$10.1
+0.09
(+0.95%)▲
2.05%
Downside
Day's Volatility :4.72%
Upside
2.73%
50.84%
Downside
52 Weeks Volatility :87.43%
Upside
74.43%
Period | Atara Biotherapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 34.12% | 1.4% | 0.0% |
6 Months | -33.59% | 3.8% | 0.0% |
1 Year | -69.91% | 15.3% | 0.0% |
3 Years | -97.73% | 11.4% | -27.4% |
Market Capitalization | 58.3M |
Book Value | -$22.61 |
Earnings Per Share (EPS) | -39.0 |
PEG Ratio | 0.0 |
Wall Street Target Price | 90.5 |
Profit Margin | -290.2% |
Operating Margin TTM | -62.41% |
Return On Assets TTM | -57.48% |
Return On Equity TTM | -2014.86% |
Revenue TTM | 62.4M |
Revenue Per Share TTM | 12.26 |
Quarterly Revenue Growth YOY | 2892.7% |
Gross Profit TTM | 63.6M |
EBITDA | -162.1M |
Diluted Eps TTM | -39.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -7.53 |
EPS Estimate Next Year | -8.77 |
EPS Estimate Current Quarter | -1.56 |
EPS Estimate Next Quarter | -5.25 |
What analysts predicted
Upside of 796.04%
Sell
Neutral
Buy
Atara Biotherapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Atara Biotherapeutics Inc | 29.6% | -33.59% | -69.91% | -97.73% | -97.04% |
Regeneron Pharmaceuticals, Inc. | -18.01% | -15.81% | -1.7% | 31.13% | 150.21% |
Biontech Se | -12.27% | 17.34% | 4.17% | -56.04% | 478.94% |
Alnylam Pharmaceuticals, Inc. | 2.34% | 76.9% | 60.41% | 45.24% | 198.24% |
Vertex Pharmaceuticals Incorporated | 10.04% | 20.33% | 30.51% | 156.8% | 152.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Atara Biotherapeutics Inc | NA | NA | 0.0 | -7.53 | -20.15 | -0.57 | NA | -22.61 |
Regeneron Pharmaceuticals, Inc. | 20.49 | 20.54 | 1.22 | 44.74 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -2.99 | -0.03 | -0.02 | NA | 85.17 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -1.87 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.27 | 0.19 | -0.03 | 0.12 | NA | 60.66 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Atara Biotherapeutics Inc | Buy | $66.0M | -97.04% | NA | -290.2% |
Regeneron Pharmaceuticals, Inc. | Buy | $91.1B | 150.21% | 20.49 | 33.61% |
Biontech Se | Buy | $26.5B | 478.94% | 160.8 | -18.75% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.8B | 198.24% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $121.6B | 152.08% | 32.84 | -4.51% |
Insights on Atara Biotherapeutics Inc
Revenue is up for the last 5 quarters, 957.0K → 28.64M (in $), with an average increase of 48.5% per quarter
Netprofit is up for the last 4 quarters, -697.97M → -190.49M (in $), with an average increase of 57.5% per quarter
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 60.4% return, outperforming this stock by 130.3%
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 45.8% return, outperforming this stock by 143.6%
Redmile Group, LLC
EcoR1 Capital, LLC
Citadel Advisors Llc
Bank of America Corp
Vanguard Group Inc
Centiva Capital LP
we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have
Organization | Atara Biotherapeutics Inc |
Employees | 165 |
CEO | Dr. Anhco Nguyen Ph.D. |
Industry | Health Technology |
Cactus Acquisition Corp 1 Ltd
$10.10
+0.95%
Rigel Resource Acquisition Corp
$10.10
+0.95%
Ft Energy Income Partners Strategy Etf
$10.10
+0.95%
Tian Ruixiang Holdings Ltd
$10.10
+0.95%
Invsc Bulletshares 2032 Corp
$10.10
+0.95%
Schwab International Dividend Equity Etf
$10.10
+0.95%
Fitell Corp
$10.10
+0.95%
Estrella Immunopharma Inc
$10.10
+0.95%
Abrdn Income Credit Strategies Fund
$10.10
+0.95%